Development of oral immunomodulatory agents in the management of multiple sclerosis

References

• FordHLGerryEJohnsonMA prospective study of the incidence, prevalence and mortality of multiple sclerosis in LeedsJ Neurol200224926026511993523
   PubMed Web of Science ®Google Scholar
• SlokaJSPryse-PhillipsWEStefanelliMIncidence and prevalence of multiple sclerosis in Newfoundland and LabradorCan J Neurol Sci200532374215825544
   PubMed Web of Science ®Google Scholar
• EbersGCTraboulseeALiDInvestigators of the 16-year Long-Term Follow-Up StudyAnalysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trialJ Neurol Neurosurg Psychiatry20108190791220562430
   PubMed Web of Science ®Google Scholar
• McCabeCChilcottJClaxtonKContinuing the multiple sclerosis risk sharing scheme is unjustifiedBMJ2010340c178620522655
   PubMed Web of Science ®Google Scholar
• MunariLLovatiRBoikoATherapy with glatiramer acetate for multiple sclerosisThe Cochrane Library42006Chichester, UKJohn Wiley & Sons, Ltd
   Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200635489991016510744
   PubMed Web of Science ®Google Scholar
• GoldROral therapies for multiple sclerosis: a review of agents in Phase III development or recently approvedCNS Drugs201125375221128693
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCEdanGDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Ann Neurol20055884084616283615
   PubMed Web of Science ®Google Scholar
• CAMMS223 Trial InvestigatorsAlemtuzumab vs interferon beta-1a in early multiple sclerosisN Engl J Med20083591786180118946064
   PubMed Web of Science ®Google Scholar
• BurtRKLohYCohenBAutologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II studyLancet Neurol200983244253 Erratum in: Lancet Neurol. 2009;8:309.19186105
   PubMed Web of Science ®Google Scholar
• ScalfariANeuhausADegenhardtAThe natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disabilityBrain20101331914192920534650
   PubMed Web of Science ®Google Scholar
• FisnikuLKBrexPAAltmannDRDisability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosisBrain200813180881718234696
   PubMed Web of Science ®Google Scholar
• OkudaDTMowryEMBeheshtianAIncidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndromeNeurology200972800805 Erratum in: Neurology. 2009;72:1284.19073949
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Natalizumab for adults with highly active relapsing-remitting multiple sclerosis NICE technology appraisal guidance 12, Issue date: August 2007. Available at: http://www.nice.org.uk/nicemedia/live/11822/36136/36136.pdf. Accessed January 1, 2011.
   Google Scholar
• JonesJLColesAJNew treatment strategies in multiple sclerosisExp Neurol2010225343920547155
   PubMed Web of Science ®Google Scholar
• DegenhardtARamagopalanSVScalfariAClinical prognostic factors in multiple sclerosis: a natural history reviewNat Rev Neurol2009567268219953117
   PubMed Web of Science ®Google Scholar
• MagliozziRHowellOVoraAMeningeal B-cell follicles in secondary progressive multiple sclerosis associated with early onset of disease and severe cortical pathologyBrain20071301089110417438020
   PubMed Web of Science ®Google Scholar
• ColesAJWingMGMolyneuxPMonoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosisAnn Neurol19994629630410482259
   PubMed Web of Science ®Google Scholar
• BurtRKCohenBARussellEHematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scoresBlood20031022373237812842989
   PubMed Web of Science ®Google Scholar
• InusahSSormaniMPCofieldSSAssessing changes in relapse rates in multiple sclerosisMult Scler2010161414142120810517
   PubMed Web of Science ®Google Scholar
• NicholasRStraubeSSchmidliHTrends in annualized relapse rates in relapsing remitting multiple sclerosis and consequences for clinical trial designMult Scler2011 In press.
   Web of Science ®Google Scholar
• NicholasRChatawayJMultiple Sclerosis: Clinical Evidence HandbookLondon, UKBMJ Publishing Group Ltd2007
   Google Scholar
• Dhib-JalbutSMechanisms of interferon beta action in multiple sclerosisMult Scler199733974019493642
   PubMed Web of Science ®Google Scholar
• AlamJGoelzSRiouxPComparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteersPharm Res1997145465499144748
   PubMed Web of Science ®Google Scholar
• RiceGPAIncorvaiaBMunariLInterferon in relapsing-remitting multiple sclerosisThe Cochrane Library42006Chichester, UKJohn Wiley & Sons, Ltd
   Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosisN Engl J Med200034389890411006365
   PubMed Web of Science ®Google Scholar
• ComiGFillipiMBarkhofFEffect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyLancet20013571576158211377645
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurol20066712421249
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationMedwatch safety information alerts2006 Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150730.htm. Accessed January 1, 2011.
   Google Scholar
• SorensenPSKoch-HenriksenNRossCAppearance and disappearance of neutralizing antibodies during interferon-beta therapyNeurology200565333915888603
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol200925656857619444532
   PubMed Web of Science ®Google Scholar
• TurnerAPWilliamsRMSloanAPInjection anxiety remains a long-term barrier to medication adherence in multiple sclerosisRehabil Psychol20095411612119618711
   PubMed Web of Science ®Google Scholar
• BornsteinMBMillerASlagleSA pilot trial of Cop 1 in exacerbating-remitting multiple sclerosisN Engl J Med19873174084143302705
   PubMed Web of Science ®Google Scholar
• DudaPWSchmiedMCCookSLGlatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJ Clin Invest200010596797610749576
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology199545126812767617181
   PubMed Web of Science ®Google Scholar
• FilippiMRovarisMRoccaMAGlatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”Neurology20015773173311524494
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis: a multicentre, randomised, parallel, open-label trialLancet Neurol2008790391418789766
   PubMed Web of Science ®Google Scholar
• O’ConnorPDevonshireVThe use of disease-modifying agents in multiple sclerosis – by the Canadian Network of MS ClinicsCan J Neurol Sci20083512713218574923
   PubMed Web of Science ®Google Scholar
• ComiGMartinelliVRodegherMPreCISe study groupEffect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialLancet20093741503151119815268
   PubMed Web of Science ®Google Scholar
• SteinmanLBlocking adhesion molecules as therapy for multiple sclerosis: natalizumabNat Rev Drug Discov2005451051815931259
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med200635491192316510745
   PubMed Web of Science ®Google Scholar
• YousryTAMajorEORyschkewitschCEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyN Engl J Med200635492493316510746
   PubMed Web of Science ®Google Scholar
• ThompsonJPNoyesKDorseyERQuantitative risk-benefit analysis of natalizumabNeurology20087135736418663181
   PubMed Web of Science ®Google Scholar
• CalabresiPAGiovannoniGConfavreuxCThe incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINELNeurology2007691391140317761550
   PubMed Web of Science ®Google Scholar
• FoxEJMechanism of action of mitoxantroneNeurology20046312 Suppl 6S15S1815623664
   PubMed Web of Science ®Google Scholar
• Martinelli BoneschiFRovarisMCapraRMitoxantrone for multiple sclerosisThe Cochrane Library42006Chichester, UKJohn Wiley & Sons, Ltd
   Google Scholar
• EdanGMillerDClanetMTherapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteriaJ Neurol Neurosurg Psychiatry1997621121189048709
   PubMed Web of Science ®Google Scholar
• HartungHPGonsetteRKonigNMitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialLancet20023602018202512504397
   PubMed Web of Science ®Google Scholar
• GhalieRGEdanGLaurentMCardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MSNeurology20025990991312297576
   PubMed Web of Science ®Google Scholar
• MartinelliVRadaelliMStraffiLMitoxantrone: benefits and risks in multiple sclerosis patientsNeurol Sci200930Suppl 2S167S17019882368
   PubMed Web of Science ®Google Scholar
• CarsonDAWassonDBTaetleRSpecific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytesBlood1983627377436136305
   PubMed Web of Science ®Google Scholar
• BrousilJARobertsRJSchleinALCladribine: an investigational immunomodulatory agent for multiple sclerosisAnn Pharmacother2006401814182116985095
   PubMed Web of Science ®Google Scholar
• KawasakiHCarreraCJPiroLDRelationship of deoxycytidine kinase and cytoplasmic 50-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosineBlood1993815976018094016
   PubMed Web of Science ®Google Scholar
• CarsonDAKayeJSeegmillerJELymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s)Proc Natl Acad Sci U S A19777456775681202960
   PubMed Web of Science ®Google Scholar
• RiceGPFilippiMComiGCladribine Study GroupCladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trialNeurology2000541145115510720289
   PubMed Web of Science ®Google Scholar
• KopadzeTDöbertMLeussinkVICladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosisEur J Neurol20091640941219175384
   PubMed Web of Science ®Google Scholar
• JaniecKWajgtAKondera-AnaszZEffect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosisMed Sci Monit20017939811208501
   PubMedGoogle Scholar
• Bartosik-PsujekHBelniakEMitosek-SzewczykKInterleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis treated with cladribineActa Neurol Scand200410939039215147461
   PubMed Web of Science ®Google Scholar
• LaugelBChallierJSiegfriedCCladribine exerts a modulatory effect of T cell activationMult Scler200814S52S53
   Google Scholar
• LiliemarkJThe clinical pharmacokinetics of cladribineClin Pharmacokinet1997321201319068927
   PubMed Web of Science ®Google Scholar
• AlbertioniFHerbgrenLJuliussonGLiliemarkJProtein binding of 2-chloro 2′-deoxyadenosine (cladribine) in healthy subjects and in patients with leukaemiaEur J Clin Pharmacol1994465635647995327
   PubMed Web of Science ®Google Scholar
• Australian Public Assessment Report for cladribine tablets122010 Available at: http://www.tga.gov.au/pmeds/auspar/auspar-movectro.pdf. Accessed March 19. http://www.tga.gov.au/pmeds/auspar/auspar-movectro.pdf. Accessed March 19. 2011.
   Google Scholar
• MatloubianMLoCGCinamonGLymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1Nature200442735536014737169
   PubMed Web of Science ®Google Scholar
• SpiegelSMilstienSSphingosine-1-phosphate: an enigmatic signalling lipidNat Rev Mol Cell Biol2003439740712728273
   PubMed Web of Science ®Google Scholar
• CysterJGChemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organsAnnu Rev Immunol20052327159
   Web of Science ®Google Scholar
• HanelPAndreaniPGralerMHErythrocytes store and release sphingosine 1-phosphate in bloodFASEB J2007211202120917215483
   PubMed Web of Science ®Google Scholar
• BrinkmannVDavisMDHeiseCEThe immune modulator FTY720 targets sphingosine 1-phosphate receptorsJ Biol Chem2002277214532145711967257
   PubMed Web of Science ®Google Scholar
• GralerMHGoetzlEJThe immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptorsFASEB J20041855155314715694
   PubMed Web of Science ®Google Scholar
• SchwabSRPereiraJPMatloubianMLymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradientsScience20053091735173916151014
   PubMed Web of Science ®Google Scholar
• WeiSHRosenHMatheuMPSphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinusesNat Immunol200561228123516273098
   PubMed Web of Science ®Google Scholar
• JoESannaMGGonzalez-CabreraPJS1P1-selective in vivo-active agonists from high-throughput screening: off the-shelf chemical probes of receptor interactions, signaling, and fateChem Biol20051270371515975516
   PubMed Web of Science ®Google Scholar
• SannaMGEnhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivoNat Chem Biol2006243444116829954
   PubMed Web of Science ®Google Scholar
• KovarikJMSchmouderRLSladeAJOverview of FTY720 clinical pharmacokinetics and pharmacologyTher Drug Monit20042658558715570180
   PubMed Web of Science ®Google Scholar
• KovarikJMHartmannSBartlettMOral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effectsBiopharm Drug Dispos2007289710417230596
   PubMed Web of Science ®Google Scholar
• SchmouderRLChoudhurySBarillaDProlonged, consistent oral absorption of FTY720. (Abstract)Am J Transplant20011475
   Google Scholar
• ZollingerMGschwindHPJinYSayerCZécriFHartmannSAbsorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathwaysDrug Metab Dispos20113919920721045200
   PubMed Web of Science ®Google Scholar
• OckenfelsHMSchultewolterTOckenfelsGThe antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine networkBr J Dermatol19981393903959767281
   PubMed Web of Science ®Google Scholar
• AsadullahKSchmidHFriedrichMInfluence of monomethylfumarate on monocytic cytokine formation eplanation for adverse and therapeutic effects in psoriasis?Arch Dermatol Res19972896236309444385
   PubMed Web of Science ®Google Scholar
• De JongRBezemerACZomerdijkTPSelective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarateEur J Immunol199626206720748814248
   PubMed Web of Science ®Google Scholar
• SchillingSGoelzSLinkerRFumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClin Exp Immunol200614510110716792679
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline controlled pilot studyEur J Neurol20061360461016796584
   PubMed Web of Science ®Google Scholar
• LitjensNHRademakerMRavensbergenBMonotheylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responsesEur J Immunol20043456557514768062
   PubMed Web of Science ®Google Scholar
• LoeweRPillingerMde MartinRDimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent mannerJ Invest Dermatol20011171363136811886496
   PubMed Web of Science ®Google Scholar
• LoeweRHolnthonerWGrogerMDimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cellsJ Immunol20021684781478711971029
   PubMed Web of Science ®Google Scholar
• WierinckxABreveJMercierDDetoxification enzyme inducers modify cytokine production in rat mixed glial cellsJ Neuroimmunol200516613214315993952
   PubMed Web of Science ®Google Scholar
• ChenXLDoddGThomasSActivation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expressionAm J Physiol Heart Circ Physiol2006290H1862H187016339837
   PubMed Web of Science ®Google Scholar
• LukashevMZengWRyanSActivation of Nrf2 and modulation of disease progression in EAE models by BG00012 (Dimethyl Fumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalitiesMult Scler200713S149
   PubMed Web of Science ®Google Scholar
• ItohKChibaTTakahashiSAn Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elementsBiochem Biophys Res Commun19972363133229240432
   PubMed Web of Science ®Google Scholar
• VenugopalRJaiswalAKNrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymesOncogene199817314531569872330
   PubMed Web of Science ®Google Scholar
• CalabreseVRavagnaAColombritaCAcetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2J Neurosci Res20057950952115641110
   PubMed Web of Science ®Google Scholar
• LiJJohnsonDCalkinsMStabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cellsToxicol Sci20058331332815525690
   PubMed Web of Science ®Google Scholar
• SatohTOkamatoSICuiJActivation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducersProc Natl Acad Sci200610376877316407140
   PubMed Web of Science ®Google Scholar
• ShihAYLiPMurphyTHA small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivoJ Neurosci200525103211033516267240
   PubMed Web of Science ®Google Scholar
• VargasMRPeharMCassinaPFibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: consequences for motor neuron survivalJ Biol Chem200527255712557915870071
   PubMed Web of Science ®Google Scholar
• ZhaoJMooreANRedellJBEnhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injuryJ Neurosci2007 19;27102401024817881530
   PubMed Web of Science ®Google Scholar
• HubbsAFBenkovicSAMillerDBVacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2Am J Pathol20071702068207617525273
   PubMed Web of Science ®Google Scholar
• NibberingPHThioBZomerdijkTPEffects of monomethylfumarate on human granulocytesJ Invest Dermatol199310137428392528
   PubMed Web of Science ®Google Scholar
• MrowietzUChristophersEAltmeyerPTreatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus ConferenceBr J Dermatol199914142442910584060
   PubMed Web of Science ®Google Scholar
• NoseworthyJHWolinskyJSLublinFDNorth American Linomide InvestigatorsLinomide in relapsing and secondary progressive MS. Part I: trial design and clinical resultsNeurology2000541726173310802775
   PubMed Web of Science ®Google Scholar
• WolinskyJSNarayanaPANoseworthyJHMRI analysis center of the University of Texas–Houston, health science center, and the North American Linomide investigatorsLinomide in relapsing and secondary progressive MS. Part II: MRI resultsNeurology2000541734174110802777
   PubMed Web of Science ®Google Scholar
• TanILLycklama à NijeholtGJPolmanCH95 Line 146/147 Study GroupLinomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trailsMult Scler200069910410773855
   PubMed Web of Science ®Google Scholar
• BrunmarkCRunströmAOhlssonLThe new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJ Neuroimmunol200213016317212225898
   PubMed Web of Science ®Google Scholar
• YangJSXuLYXiaoBGLaquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis ratsJ Neuroimmunol20041563915465591
   PubMed Web of Science ®Google Scholar
• WegnerCPfortnerRBruckWLaquinimod rescue therapy in mice with experimental autoimmune encephalomyelitisMult Scler201016S41S196 Abstract P251.
   Web of Science ®Google Scholar
• GurevichMGritzmanTOrbachRLaquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression studyJ Neuroimmunol2010221879420347159
   PubMed Web of Science ®Google Scholar
• RunstromALeandersonTOhlssonLInhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type miceJ Neuroimmunol2006173697816472873
   PubMed Web of Science ®Google Scholar
• WegnerCStadelmannCPförtnerRLaquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitisJ Neuroimmunol201022713314320684995
   PubMed Web of Science ®Google Scholar
• PreiningerovaJOral laquinimod therapy in relapsing multiple sclerosisExpert Opin Investig Drugs200918985989
   PubMed Web of Science ®Google Scholar
• FoxRIHerrmannMLFrangouCGShort analytical review: mechanism of action for leflunomide in rheumatoid arthritisClin Immunol19999319820810600330
   PubMed Web of Science ®Google Scholar
• UllrichAKnechtKFriesMRecombinant expression of Nterminal truncated mutants of the membrane bound mouse, rat, and human flavozyme dihydroorotate dehydrogenaseEur J Biochem20012681861186811248707
   PubMedGoogle Scholar
• BruneauJ-MYeaCMSpinella-JaegleSPurification of human dihydro-orotate dehydrogenase and its inhibition by A771726, the active metabolite of leflunomideBiochem J19983362993039820804
   PubMed Web of Science ®Google Scholar
• GreeneSWatanabeKBraatz-TrulsonJInhibition of dihydro-orotate dehydrogenase by the immunosuppressive agent leflunomideBiochem Pharmacol1995508618677575649
   PubMed Web of Science ®Google Scholar
• CherwinskiHMCohnRGCheungPThe immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesisJ Pharmacol Exp Therap1995275104310497473131
   PubMed Web of Science ®Google Scholar
• RuckemannKFairbanksLDCarreyEALeflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humansJ Biol Chem199827321682216919705303
   PubMed Web of Science ®Google Scholar
• SiemaskoKFChongASWilliamsJWRegulation of B cell function by the immunosuppressive agent leflunomideTransplant199627635642
   Web of Science ®Google Scholar
• SiemaskoKChongASJackHMInhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 productionJ Immunol1998160158115889469413
   PubMed Web of Science ®Google Scholar
• XuXWilliamsJWBremerEGInhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomideJ Biol Chem199527012398124037759480
   PubMed Web of Science ®Google Scholar
• MiljkovicDSamardzicTMostaricaSMLeflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytesBrain Res200188933133811166726
   PubMed Web of Science ®Google Scholar
• MladenovicVDomljanZRozmanBSafety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II studyArthritis Rheum199538159516037488280
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci U S A199693171617208643695
   PubMed Web of Science ®Google Scholar
• RomineJSSipeJCKoziolJAA double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosisProc Assoc Am Physicians199911135449893155
   PubMedGoogle Scholar
• GiovannoniGComiGCookSCLARITY Study GroupA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med201036241642620089960
   PubMed Web of Science ®Google Scholar
• RieckmannPGiovannoniGCookSDCladribine tablets in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRibine tablets Treating multiple sclerosis orallY) extension studyMult Scler200814S161S162
   Web of Science ®Google Scholar
• MontalbanXCohenBAJefferyDRONWARD Study GroupOral cladribine added to interferon beta-1a for active multiple sclerosis: a 96-week, double- blind, placebo-controlled phase IIb studyMult Scler200713Suppl 2S245
   Google Scholar
• Merck SeronoMerck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis Press release 18-09-2008. http://www.merckserono.net/corp.merckserono/en/images/20080918_en_tcm112_21562.pdf. Accessed October 21, 2010.
   Google Scholar
• DasanuCAAlexandrescuDTRisk of additional cancers in untreated and treated hairy cell leukemia patientsExpert Opin Pharmacother201011415020001428
   PubMed Web of Science ®Google Scholar
• US Food and Drugs AdministrationFDA approves first oral drug to reduce MS relapses2010 Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm. Accessed December 27, 2010.
   Google Scholar
• FujinoMFuneshimaNKitazawaYAmelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatmentJ Pharmacol Exp Ther2003305707712649354
   PubMed Web of Science ®Google Scholar
• WebbMThamC-SLinF-FSphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL miceJ Neuroimmunol200415310812115265669
   PubMed Web of Science ®Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med20063551124114016971719
   PubMed Web of Science ®Google Scholar
• O’ConnorPComiGMontalbanXOral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension studyNeurology200972737919122034
   PubMed Web of Science ®Google Scholar
• MontalbanXO’ConnorPAntelJOral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four-year results from a phase II extensionNeurology200972Suppl 3A313 Abstract.
   Google Scholar
• KapposLRadueEWO’ConnorPFREEDOMS Study GroupA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med201036238740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGTRANSFORMS Study GroupOral fingolimod or intramuscularinterferon for relapsing multiple sclerosisN Engl J Med201036240241520089954
   PubMed Web of Science ®Google Scholar
• KapposLMillerDHMacManusDGBG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosisMult Scler200612Suppl 1S85
   Google Scholar
• HoefnagelJJThioHBWillemzeRLong-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasisBr J Dermatol200314936336912932244
   PubMed Web of Science ®Google Scholar
• RuffiniFBergamaschiAMarinaroCLaquinimod prevents the inflammation-induced derangement of neurogenic niches in experimental autoimmune encephalomyelitis miceMult Scler201016S41S196 Abstract P885.
   Google Scholar
• ThöneJLeeDSeubertSLaquinimod ameliorates experimental autoimmune encephalomyelitis via BDNF-dependent mechanismsMult Scler201016S41S196 Abstract P881.
   Web of Science ®Google Scholar
• PolmanCBarkhofFSandberg-WollheimMLaquinimod in Relapsing MS Study GroupTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology20056498799115781813
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMLAQ/5062 Study GroupEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet20083712085209218572078
   PubMed Web of Science ®Google Scholar
• TEVA press releaseTeva announces successful results of phase III study with oral Laquinomod for multiple sclerosis2010 Available at: http://www.tevapharm.com/pr/2010/pr_976.asp. Accessed December 24, 2010.
   Google Scholar
• MerrillJEHanakSPuSFTeriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Neurol20092568910319169851
   PubMed Web of Science ®Google Scholar
• ConfavreuxCO’ConnorPWFreedmanMSSafety of teriflunomide in the treatment of relapsing multiple sclerosis: results over an 8-year extensionMult Scler201016S41S196 Abstract P833.
   Google Scholar
• LiDKO’ConnorPWConfavreuxCLong-term brain MRI and clinical assessments of teriflunomide for the treatment of multiple sclerosis: extension of a phase II studyMult Scler201016S41S196 Abstract P431.
   Google Scholar
• O’ConnorPWolinskyJConfavreuxCA placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomesMult Scler201016S41S196 Abstract P79.
   Google Scholar
• WolinskyJO’ConnorPConfavreuxCA placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: magnetic resonance imaging (MRI) outcomesMult Scler201016S41S196 Abstract P982.
   Google Scholar
• LilyOMcFaddenEHensorEDisease-specific quality of life in multiple sclerosis: the effect of disease modifying treatmentMult Scler20061280881317263011
   PubMed Web of Science ®Google Scholar
• JongenPJLehnickDSandersEFOCUS study groupHealth-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre studyHealth Qual Life Outcomes20101513321078142
   PubMed Web of Science ®Google Scholar
• DaughertyKKButlerJSMattinglyMFactors leading patients to discontinue multiple sclerosis therapiesJ Amer Pharm Assoc200545371375
   Google Scholar
• DevonshireVLapierreYMacdonellRGAP Study GroupThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol201118697720561039
   PubMed Web of Science ®Google Scholar
• BermelRAWeinstock-GuttmanBBourdetteDIntramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up studyMult Scler20101658859620167591
   PubMed Web of Science ®Google Scholar
• PiehlFHolménCHillertJSwedish natalizumab (Tysabri) multiple sclerosis surveillance studyNeurol Sci201131Suppl 328929320556456
   PubMed Web of Science ®Google Scholar
• RudickRAMillerDHassSAFFIRM and SENTINEL InvestigatorsHealth-related quality of life in multiple sclerosis: effects of natalizumabAnn Neurol20076233534617696126
   PubMed Web of Science ®Google Scholar
• O’ConnorPFilippiMArnasonBBEYOND Study Group250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyLancet Neurol2009888989719729344
   PubMed Web of Science ®Google Scholar
• BornerMScheithauerWTwelvesCAnswering patients’ needs: oral alternatives to intravenous therapyOncologist20016Suppl 4121611585969
   PubMed Web of Science ®Google Scholar
• Meca-LallanaJEde Mingo-CasadoPAmorin-DíazMEffects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot studyClin Ther2010321061106620637960
   PubMed Web of Science ®Google Scholar
• GoebJLEvenCNicolasGPsychiatric side effects of interferon-beta in multiple sclerosisEur Psychiatry20062118619316386408
   PubMed Web of Science ®Google Scholar
• BuljevacDFlachHZHopWCProspective study on the relationship between infections and multiple sclerosis exacerbationsBrain200212595296011960885
   PubMed Web of Science ®Google Scholar
• GiannantoniAScivolettoGDi StasiSMGrassoMGVespasianiGCastellanoVUrological dysfunctions and upper urinary tract involvement in multiple sclerosis patientsNeurourol Urodyn19981789989514141
   PubMed Web of Science ®Google Scholar
• StuveOGoldRChanAAlpha4-Integrin antagonism with natalizumab: effects and adverse effectsJ Neurol2008255Suppl 6586519300961
   PubMed Web of Science ®Google Scholar
• CliffordDBDe LucaASimpsonDMNatalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesLancet Neurol2010943844620298967
   PubMed Web of Science ®Google Scholar
• GorelikLLernerMBixlerSAnti-JC virus antibodies: implications for PML risk stratificationAnn Neurol20106829530320737510
   PubMed Web of Science ®Google Scholar
• PanzaraMABozicCSandrockAWMore on melanoma with transdifferentiationN Engl J Med20087335999 author reply9910018596284
   PubMed Web of Science ®Google Scholar
• AmatoMPPortaccioEGhezziAMS Study Group of the Italian Neurological SocietyPregnancy and fetal outcomes after interferon-β exposure in multiple sclerosisNeurology2010751794180221079181
   PubMed Web of Science ®Google Scholar
• BiogenAvonex (interferon-1a): product monographBiogen1998
   Google Scholar
• FrancisGCollinsWBurtinPFingolimod (NDA 22-527), Briefing document2010 Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM214675.pdf. Accessed January 1, 2011.
   Google Scholar
• MuraroPAUccelliAImmuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MSResults Probl Cell Differ20105123725719513637
   PubMedGoogle Scholar
• ChatawayJWhen confronted by a patient with the radiologically isolated syndromePract Neurol20101027127720858628
   PubMedGoogle Scholar
• KortewegTTintoreMUitdehaagBMRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up studyLancet Neurol2006522122716488377
   PubMed Web of Science ®Google Scholar
• BarkhofFRoccaMFrancisGEarly Treatment of Multiple Sclerosis Study GroupValidation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1aAnn Neurol20035371872412783417
   PubMed Web of Science ®Google Scholar
• HutchinsonMKapposLCalabresiPAAFFIRM and SENTINEL InvestigatorsThe efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELJ Neurol200925640541519308305
   PubMed Web of Science ®Google Scholar